Updated from 8:43 a.m. EDTForest Laboratories ( FRX) said its fiscal-year forecast would be lower than the company previously planned, sending its shares lower Tuesday. The New York-based drugmaker said revenue for the year ending March 31 would be around $3 billion. Forest previously predicted that fiscal-year revenue would be slightly better than the previous year's $3.16 billion. The Wall Street consensus estimate is $3.07 billion. Forest said earnings were still on track to meet its expectation of $2.30, excluding special items. Analysts polled by Thomson First Call expect an EPS of $2.32. A one-time tax benefit will push the full-year EPS to $2.40, Forest said. The benefit relates to Forest repatriating earnings from foreign divisions under a one-time tax holiday law signed by President Bush last year. The law reduces the tax to 5.25% from 35%. Forest's shares were lately down 88 cents, or 2.4%, to $35.47, after having fallen as low as $34.68. The company issued its fiscal-year forecast as it released second-quarter financial results. Quarterly earnings beat Wall Street's consensus estimate, but revenue fell below the average prediction. Forest earned $204.9 million, or 59 cents a share, on revenue of $736.5 million for the three months ended Sept. 30. The Thomson First Call consensus expected a profit of $189 million, or 56 cents a share, on revenue of $751.6 million. For the same period last year, Forest earned $295.3 million, or 79 cents, on revenue of $856.7 million. Forest's weaker performance vs. the same period last year was a mixture of the expected and the unexpected. Forest had been expecting a beating for its antidepressant Celexa, which is subject to many generic competitors. Celexa produced only $5.1 million in sales for the second quarter, where as for the same period last year, Celexa recorded $256.4 million.